![Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma](https://i3.wp.com/mma.prnewswire.com/media/597589/4648918/Norgine_Logo.jpg?p=thumbnail&w=420&resize=420,280&ssl=1 "Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma"){kind=logo}
Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
Back to media releasesNext media release LONDON, Jan. 7, 2025 /PRNewswire/ --…
Tag: (difluoromethylornithine